Public articles linked to the same research event.
Biochimie This review synthesizes the 15 MAPK homologues across pathogenic Leishmania species, linking individual kinases to parasite differentiation, intracellular survival, stress tolerance, motility, virulence and drug response, distinguishing experimentally validated mechanistic targets from computationally proposed candidates, and evaluating small-molecule and natural-product inhibitors, drug repurposing, structure-guided approaches, and emerging contributions from molecular dynamics, AlphaFold-based modelling, artificial intelligence and nanotechnology, while noting evidence for MAPK10 as a vaccine-associated antigen.
This review synthesizes the 15 MAPK homologues across pathogenic Leishmania species, linking individual kinases to parasite differentiation, intracellular survival, stress tolerance, motility, virulence and drug response, distinguishing experimentally validated mechanistic targets from computationally proposed candidates, and evaluating small-molecule and natural-product inhibitors, drug repurposing, structure-guided approaches, and emerging contributions from molecular dynamics, AlphaFold-based modelling, artificial intelligence and nanotechnology, while noting evidence for MAPK10 as a vaccine-associated antigen.
This review synthesizes the 15 MAPK homologues across pathogenic Leishmania species, linking individual kinases to parasite differentiation, intracellular survival, stress tolerance, motility, virulence and drug response, distinguishing experimentally validated mechanistic targets from computationally proposed candidates, and evaluating small-molecule and natural-product inhibitors, drug repurposing, structure-guided approaches, and emerging contributions from molecular dynamics, AlphaFold-based modelling, artificial intelligence and nanotechnology, while noting evidence for MAPK10 as a vaccine-associated antigen.
This review synthesizes the 15 MAPK homologues across pathogenic Leishmania species, linking individual kinases to parasite differentiation, intracellular survival, stress tolerance, motility, virulence and drug response, distinguishing experimentally validated mechanistic targets from computationally proposed candidates, and evaluating small-molecule and natural-product inhibitors, drug repurposing, structure-guided approaches, and emerging contributions from molecular dynamics, AlphaFold-based modelling, artificial intelligence and nanotechnology, while noting evidence for MAPK10 as a vaccine-associated antigen.